# BESCHWERDEKAMMERN DES EUROPÄISCHEN PATENTAMTS

# BOARDS OF APPEAL OF THE EUROPEAN PATENT OFFICE

CHAMBRES DE RECOURS DE L'OFFICE EUROPÉEN DES BREVETS

#### Internal distribution code:

- (A) [ ] Publication in OJ
- (B) [ ] To Chairmen and Members
- (C) [ ] To Chairmen
- (D) [X] No distribution

# Datasheet for the decision of 27 March 2025

Case Number: T 0142/23 - 3.3.04

Application Number: 17001347.8

Publication Number: 3292873

IPC: A61K39/395, C07K16/28,

A61K39/39

Language of the proceedings: EN

#### Title of invention:

Combination of vaccination and inhibition of the PD-1 pathway

#### Patent Proprietor:

CureVac SE

#### Opponents:

Strawman Limited
Merck Patent GmbH
BioNTech SE
eTheRNA Immunotherapies NV
Pfizer Inc.
James Poole Limited

# Relevant legal provisions:

EPC Art. 113(2)

# Keyword:

Basis of decision — text or agreement to text withdrawn by patent proprietor  $\$ 

## Decisions cited:

T 0186/84, T 0646/08, T 0728/11, T 2434/18, T 0477/22



# Beschwerdekammern **Boards of Appeal** Chambres de recours

Boards of Appeal of the European Patent Office Richard-Reitzner-Allee 8 85540 Haar **GERMANY** Tel. +49 (0)89 2399-0

Case Number: T 0142/23 - 3.3.04

# DECISION of Technical Board of Appeal 3.3.04 of 27 March 2025

Appellant: CureVac SE

Friedrich-Miescher-Straße 15 (Patent Proprietor)

72076 Tübingen (DE)

Graf von Stosch, Andreas Representative:

Graf von Stosch

Patentanwaltsgesellschaft mbH

Prinzregentenstraße 22 80538 München (DE)

Strawman Limited Respondent: Orchard Lea,

(Opponent 1) Horns Lane, Combe, Whitney,

Oxfordshire OX29 8NH (GB)

Vossius & Partner Representative:

Patentanwälte Rechtsanwälte mbB

Siebertstrasse 3 81675 München (DE)

Respondent: Merck Patent GmbH

Frankfurter Strasse 250 (Opponent 2)

64293 Darmstadt (DE)

Respondent: BioNTech SE

An der Goldgrube 12 (Opponent 3)

55131 Mainz (DE)

Thomann, William John Representative:

ZSP

Patentanwälte PartG mbB

Hansastraße 32 80686 München (DE) Respondent: eTheRNA Immunotherapies NV

Galileilaan 19 (Opponent 4)

2845 Niel (BE)

Representative: Arnold & Siedsma

> Bezuidenhoutseweg 57 2594 AC The Hague (NL)

Respondent: Pfizer Inc.

66 Hudson Boulevard East (Opponent 5)

New York, NY 10001-2192 (US)

Representative: Dörries, Hans Ulrich

df-mp Patentanwälte Rechtsanwälte PartG mbB

Theatinerstraße 16 80333 München (DE)

Respondent: James Poole Limited One Southampton Row (Opponent 6)

London WC1B 5HA (GB)

Representative: Carpmaels & Ransford LLP

> One Southampton Row London WC1B 5HA (GB)

Decision under appeal: Decision of the Opposition Division of the

> European Patent Office posted on 22 December 2022 revoking European patent No. 3 292 873

pursuant to Article 101(3)(b) EPC

#### Composition of the Board:

Chairwoman M. Pregetter

Members: B. Rutz

L. Bühler

- 1 - T 0142/23

### Summary of Facts and Submissions

- I. The patent proprietor (appellant) filed an appeal against the opposition division's decision revoking European patent No. 3 292 873 (the patent in suit).
- II. With their statement setting out the grounds of appeal, the appellant requested that the decision under appeal be set aside and that the patent be maintained based on the claims of the main request or, alternatively, on the set of claims of auxiliary requests 1 to 6.
- III. In their reply to the appellants' statement of grounds of appeal, opponents 1 and 3 (respondents) requested that the appeal be dismissed.
- IV. The board issued a summons to oral proceedings and a communication under Article 15(1) RPBA.
- V. With a letter dated 26 March 2025 the appellant withdrew the agreement with the text of the patent as granted according to Article 113(2) EPC, declared not to file a replacement text and withdrew all pending requests.

#### Reasons for the Decision

1. According to the principle of party disposition established by Article 113(2) EPC, the EPO shall examine and decide on the European patent only in the text submitted to it or agreed upon by the proprietor of the patent.

- 2 - T 0142/23

- 2. In view of the appellant's (patent proprietor's) statement (see point V. above), there is no approved text on the basis of which the board could consider the appeal. It is also no longer possible to take a decision as to substance because the absence of an approved text precludes any substantive examination of the alleged impediments to patentability (T 186/84, OJ 1986, 79, point 5 of the Reasons; T 646/08, point 4 of the Reasons and T 2434/18, point 4 of the Reasons).
- In a situation such as the present one, where the patent proprietor has appealed a decision of the opposition division revoking its patent and where the appeal becomes devoid of subject-matter for substantive examination following the withdrawal of the patent proprietor's agreement to any text for the maintenance of the patent, the appeal proceedings are to be terminated, and the decision under appeal becomes final (see T 728/11, point 3; T 477/22, point 3).

### Order

#### For these reasons it is decided that:

The appeal proceedings are terminated.

- 3 - T 0142/23

The Registrar:

The Chairwoman:



I. Aperribay

M. Pregetter

Decision electronically authenticated